ZCMD – Zhongchao Inc

Float Short %

1.03

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

1.11

Target Price

Analyst Recom

Performance Q

6.73

Relative Volume

0.16

Beta

-0.06

Ticker: ZCMD

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	ZCMD	0.92	N/A	N/A	0
2025-08-18	ZCMD	0.92	N/A	N/A	0
2025-08-19	ZCMD	0.8811	N/A	N/A	0
2025-08-20	ZCMD	0.8881	N/A	N/A	0
2025-08-21	ZCMD	0.901	N/A	N/A	0
2025-08-22	ZCMD	0.86	N/A	N/A	0
2025-08-25	ZCMD	0.94	N/A	N/A	0
2025-08-26	ZCMD	0.9753	N/A	N/A	0
2025-08-27	ZCMD	0.98	N/A	N/A	0
2025-08-28	ZCMD	1.04	N/A	N/A	0
2025-08-29	ZCMD	1	N/A	N/A	0
2025-09-02	ZCMD	0.9709	N/A	N/A	0
2025-09-03	ZCMD	0.9887	N/A	N/A	0
2025-09-04	ZCMD	1	N/A	N/A	0
2025-09-05	ZCMD	0.953	N/A	N/A	0
2025-09-08	ZCMD	1.02	N/A	N/A	0
2025-09-09	ZCMD	1.1599	N/A	N/A	0
2025-09-10	ZCMD	1.08	N/A	N/A	0
2025-09-11	ZCMD	1.0913	N/A	N/A	0
2025-09-12	ZCMD	1.12	N/A	N/A	0
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	ZCMD	0.87	-	-	-
2025-08-18	ZCMD	0.93	-	-	-
2025-08-19	ZCMD	0.95	-	-	-
2025-08-20	ZCMD	0.89	-	-	-
2025-08-21	ZCMD	0.89	-	-	-
2025-08-22	ZCMD	0.92	-	-	-
2025-08-25	ZCMD	0.92	-	-	-
2025-08-26	ZCMD	0.98	-	-	-
2025-08-28	ZCMD	1.02	-	-	-
2025-08-29	ZCMD	1.01	-	-	-
2025-09-02	ZCMD	0.97	-	-	-
2025-09-03	ZCMD	0.98	-	-	-
2025-09-04	ZCMD	1.01	-	-	-
2025-09-05	ZCMD	0.95	-	-	-
2025-09-08	ZCMD	1.02	-	-	-
2025-09-09	ZCMD	1.12	-	-	-
2025-09-10	ZCMD	1.08	-	-	-
2025-09-11	ZCMD	1.12	-	-	-
2025-09-12	ZCMD	1.11	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	ZCMD	0.00	12.89	1.09
2025-08-18	ZCMD	0.00	12.11	1.09
2025-08-19	ZCMD	0.00	12.11	1.09
2025-08-20	ZCMD	0.00	12.11	1.09
2025-08-21	ZCMD	0.00	12.11	1.09
2025-08-22	ZCMD	0.00	12.11	1.09
2025-08-25	ZCMD	0.00	197.06	1.09
2025-08-26	ZCMD	0.00	197.06	1.09
2025-08-27	ZCMD	0.00	197.06	1.09
2025-08-28	ZCMD	0.00	197.06	1.09
2025-08-29	ZCMD	0.00	197.06	1.09
2025-09-02	ZCMD	0.00	159.96	1.09
2025-09-03	ZCMD	0.00	159.96	1.09
2025-09-04	ZCMD	0.00	159.96	1.09
2025-09-05	ZCMD	0.00	159.96	1.09
2025-09-08	ZCMD	0.00	206.83	1.09
2025-09-09	ZCMD	0.00	206.83	1.09
2025-09-10	ZCMD	0.00	206.83	1.09
2025-09-11	ZCMD	0.00	206.83	1.03
2025-09-12	ZCMD	0.00	206.83	1.03
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

206.83

Beta

-0.06

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.3

Max Drawdown 5-Year %

-96.8

Target Price

P/E

Forward P/E

PEG

P/S

1.77

P/B

1.35

P/Free Cash Flow

EPS

-0.12

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-4.05

Relative Volume

0.16

Return on Equity vs Sector %

-28

Return on Equity vs Industry %

-18.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Zhongchao Inc.

Sector: Healthcare

Industry: Health Information Services

Employees: 111

Zhongchao Inc. provides healthcare information, education, and training services to healthcare professionals under their MDMOOC brand in the People's Republic of China. It operates through two segments, MDMOOC services, and Sales of Patented Drugs. The company offers patient management services in the tumor and rare diseases field, internet healthcare services, and pharmaceutical services, and operates an online information platform. It also provides online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes on popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content. The company offers its services through its MDMOOC online platform, including the MDMOOC mobile app, MOOC Medical WeChat subscription account, and MDMOOC website, and patient management services through an IT system under the Zhongxun brand, WeChat mini program, and Zhongxin Health WeChat mini program. It serves enterprises and non-profit organizations, including medical associations, medical institutions, medical journals, medical foundations, and hospitals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. Zhongchao Inc. was founded in 2012 and is headquartered in Shanghai, China.

stock quote shares ZCMD – Zhongchao Inc Stock Price stock today

news today ZCMD – Zhongchao Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ZCMD – Zhongchao Inc yahoo finance google finance

stock history ZCMD – Zhongchao Inc invest stock market

stock prices ZCMD premarket after hours

ticker ZCMD fair value insiders trading

XTLB – X.T.L. Biopharmaceuticals Ltd. ADR

Float Short %

0.13

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

1.35

Target Price

Analyst Recom

Performance Q

13.4

Relative Volume

0.11

Beta

1.15

Ticker: XTLB

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	XTLB	1.41	N/A	N/A	0
2025-08-18	XTLB	1.36	N/A	N/A	0
2025-08-19	XTLB	1.32	N/A	N/A	0
2025-08-20	XTLB	1.25	N/A	N/A	0
2025-08-21	XTLB	1.24	N/A	N/A	0
2025-08-22	XTLB	1.16	N/A	N/A	0
2025-08-25	XTLB	1.2258	N/A	N/A	0
2025-08-26	XTLB	1.18	N/A	N/A	0
2025-08-27	XTLB	1.17	N/A	N/A	0
2025-08-28	XTLB	1.11	N/A	N/A	0
2025-08-29	XTLB	1.23	N/A	N/A	0
2025-09-02	XTLB	1.19	N/A	N/A	0
2025-09-03	XTLB	1.2	N/A	N/A	0
2025-09-04	XTLB	1.25	N/A	N/A	0
2025-09-05	XTLB	1.2464	N/A	N/A	0
2025-09-08	XTLB	1.28	N/A	N/A	0
2025-09-09	XTLB	1.48	N/A	N/A	0
2025-09-10	XTLB	1.42	N/A	N/A	0
2025-09-11	XTLB	1.395	N/A	N/A	0
2025-09-12	XTLB	1.35	N/A	N/A	0
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	XTLB	1.42	-	-	-
2025-08-18	XTLB	1.36	-	-	-
2025-08-19	XTLB	1.32	-	-	-
2025-08-20	XTLB	1.30	-	-	-
2025-08-21	XTLB	1.26	-	-	-
2025-08-22	XTLB	1.17	-	-	-
2025-08-25	XTLB	1.20	-	-	-
2025-08-26	XTLB	1.18	-	-	-
2025-08-28	XTLB	1.23	-	-	-
2025-08-29	XTLB	1.23	-	-	-
2025-09-02	XTLB	1.26	-	-	-
2025-09-03	XTLB	1.19	-	-	-
2025-09-04	XTLB	1.19	-	-	-
2025-09-05	XTLB	1.25	-	-	-
2025-09-08	XTLB	1.29	-	-	-
2025-09-09	XTLB	1.49	-	-	-
2025-09-10	XTLB	1.50	-	-	-
2025-09-11	XTLB	1.39	-	-	-
2025-09-12	XTLB	1.35	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	XTLB	0.00	1.98	0.15
2025-08-18	XTLB	0.00	1.98	0.15
2025-08-19	XTLB	0.00	1.98	0.15
2025-08-20	XTLB	0.00	1.98	0.15
2025-08-21	XTLB	0.00	1.98	0.15
2025-08-22	XTLB	0.00	1.98	0.15
2025-08-25	XTLB	0.00	-88.50	0.15
2025-08-26	XTLB	0.00	-88.50	0.15
2025-08-27	XTLB	0.00	-88.50	0.16
2025-08-28	XTLB	0.00	-88.50	0.16
2025-08-29	XTLB	0.00	-88.50	0.16
2025-09-02	XTLB	0.00	-89.26	0.16
2025-09-03	XTLB	0.00	-89.26	0.16
2025-09-04	XTLB	0.00	-89.26	0.16
2025-09-05	XTLB	0.00	-89.26	0.16
2025-09-08	XTLB	0.00	-88.10	0.16
2025-09-09	XTLB	0.00	-88.10	0.16
2025-09-10	XTLB	0.00	-88.10	0.16
2025-09-11	XTLB	0.00	-88.10	0.13
2025-09-12	XTLB	0.00	-88.10	0.13
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-88.1

Beta

1.15

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

79.8

Max Drawdown 5-Year %

-85.4

Target Price

P/E

Forward P/E

PEG

P/S

26.42

P/B

2.19

P/Free Cash Flow

EPS

-0.11

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-227.72

Relative Volume

0.11

Return on Equity vs Sector %

-43.8

Return on Equity vs Industry %

-30.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

XTL Biopharmaceuticals Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 10

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

stock quote shares XTLB – X.T.L. Biopharmaceuticals Ltd. ADR Stock Price stock today

news today XTLB – X.T.L. Biopharmaceuticals Ltd. ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch XTLB – X.T.L. Biopharmaceuticals Ltd. ADR yahoo finance google finance

stock history XTLB – X.T.L. Biopharmaceuticals Ltd. ADR invest stock market

stock prices XTLB premarket after hours

ticker XTLB fair value insiders trading

XNCR – Xencor Inc

Float Short %

14.37

Margin Of Safety %

Put/Call OI Ratio

1.04

EPS Next Q Diff

-0.33

EPS Last/This Y

1.01

EPS This/Next Y

-0.26

Price

8.6

Target Price

24.1

Analyst Recom

1.5

Performance Q

-8.8

Relative Volume

1.09

Beta

0.88

Ticker: XNCR

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	XNCR	7.68	0.27	0.00	294
2025-08-18	XNCR	7.82	0.18	0.00	158
2025-08-19	XNCR	7.58	0.16	999.99	170
2025-08-20	XNCR	7.51	0.19	999.99	174
2025-08-21	XNCR	7.44	1.16	0.55	316
2025-08-22	XNCR	8.4	1.16	0.55	316
2025-08-25	XNCR	7.99	1.28	0.00	314
2025-08-26	XNCR	7.91	1.21	20.75	322
2025-08-27	XNCR	8.02	1.21	20.75	322
2025-08-28	XNCR	8.05	1.60	0.00	416
2025-08-29	XNCR	8.12	1.60	0.00	416
2025-09-02	XNCR	8.54	1.60	0.00	416
2025-09-03	XNCR	8.32	1.60	0.00	416
2025-09-04	XNCR	8.37	1.51	0.00	425
2025-09-05	XNCR	8.55	1.50	0.00	427
2025-09-08	XNCR	8.41	1.23	0.00	464
2025-09-09	XNCR	8.3	1.23	0.00	464
2025-09-10	XNCR	8.36	1.17	0.00	474
2025-09-11	XNCR	8.48	1.18	0.00	473
2025-09-12	XNCR	8.59	1.04	0.00	502
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	XNCR	7.68	-1.2	-	-2.58
2025-08-18	XNCR	7.81	0.0	-	-2.58
2025-08-19	XNCR	7.59	0.0	-	-2.58
2025-08-20	XNCR	7.51	0.0	-	-2.58
2025-08-21	XNCR	7.45	0.0	-	-2.58
2025-08-22	XNCR	8.41	0.0	-	-2.58
2025-08-25	XNCR	8.00	-0.4	-	-2.55
2025-08-26	XNCR	7.90	-0.4	-	-2.55
2025-08-28	XNCR	8.05	-0.4	-	-2.55
2025-08-29	XNCR	8.13	-0.4	-	-2.55
2025-09-02	XNCR	8.55	-0.4	-	-2.55
2025-09-03	XNCR	8.32	-0.4	-	-2.55
2025-09-04	XNCR	8.36	-0.4	-	-2.55
2025-09-05	XNCR	8.55	-0.4	-	-2.57
2025-09-08	XNCR	8.41	-0.4	-	-2.57
2025-09-09	XNCR	8.31	-0.4	-	-2.57
2025-09-10	XNCR	8.35	-0.4	-	-2.57
2025-09-11	XNCR	8.50	-0.4	-	-2.57
2025-09-12	XNCR	8.60	-0.4	-	-2.57
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	XNCR	-1.35	7.10	13.82
2025-08-18	XNCR	-1.35	7.95	13.82
2025-08-19	XNCR	-1.35	7.95	13.82
2025-08-20	XNCR	-1.35	7.95	13.82
2025-08-21	XNCR	-1.35	7.95	13.82
2025-08-22	XNCR	-1.35	7.95	13.82
2025-08-25	XNCR	-1.35	5.61	13.82
2025-08-26	XNCR	-1.35	5.61	13.82
2025-08-27	XNCR	-1.35	5.61	14.23
2025-08-28	XNCR	-1.35	5.61	14.23
2025-08-29	XNCR	-1.35	5.61	14.23
2025-09-02	XNCR	-1.35	5.58	14.21
2025-09-03	XNCR	-1.38	5.58	14.21
2025-09-04	XNCR	-1.38	5.58	14.21
2025-09-05	XNCR	-1.38	5.58	14.21
2025-09-08	XNCR	-1.38	5.61	14.21
2025-09-09	XNCR	-1.38	5.61	14.21
2025-09-10	XNCR	-1.38	5.61	14.21
2025-09-11	XNCR	-1.35	5.61	14.37
2025-09-12	XNCR	-0.51	5.61	14.37
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.41

Avg. EPS Est. Current Quarter

-0.71

Avg. EPS Est. Next Quarter

-0.74

Insider Transactions

-0.51

Institutional Transactions

5.61

Beta

0.88

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

85.3

Max Drawdown 5-Year %

-87

Target Price

24.1

P/E

Forward P/E

PEG

P/S

4.17

P/B

0.99

P/Free Cash Flow

EPS

-2.42

Average EPS Est. Cur. Y

-2.57

EPS Next Y. (Est.)

-2.83

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-116.44

Relative Volume

1.09

Return on Equity vs Sector %

-52.5

Return on Equity vs Industry %

-39.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.36

EBIT Estimation

Xencor, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 250

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

stock quote shares XNCR – Xencor Inc Stock Price stock today

news today XNCR – Xencor Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch XNCR – Xencor Inc yahoo finance google finance

stock history XNCR – Xencor Inc invest stock market

stock prices XNCR premarket after hours

ticker XNCR fair value insiders trading

XAIR – Beyond Air Inc

Float Short %

6.54

Margin Of Safety %

Put/Call OI Ratio

0.01

EPS Next Q Diff

1.28

EPS Last/This Y

11.55

EPS This/Next Y

1.4

Price

2.45

Target Price

11.2

Analyst Recom

Performance Q

-33.72

Relative Volume

0.17

Beta

0.28

Ticker: XAIR

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	XAIR	2.33	0.01	0.00	4506
2025-08-18	XAIR	2.365	0.01	0.00	4506
2025-08-19	XAIR	2.28	0.01	0.00	4506
2025-08-20	XAIR	2.13	0.01	0.00	4506
2025-08-21	XAIR	2.06	0.01	0.00	4506
2025-08-22	XAIR	2.245	N/A	N/A	0
2025-08-25	XAIR	2.27	N/A	N/A	0
2025-08-26	XAIR	2.26	N/A	N/A	0
2025-08-27	XAIR	2.29	N/A	N/A	0
2025-08-28	XAIR	2.18	N/A	N/A	0
2025-08-29	XAIR	2.22	N/A	N/A	0
2025-09-02	XAIR	2.21	N/A	N/A	0
2025-09-03	XAIR	2.31	N/A	N/A	0
2025-09-04	XAIR	2.145	N/A	N/A	0
2025-09-05	XAIR	2.21	N/A	N/A	0
2025-09-08	XAIR	3.42	0.01	0.01	4175
2025-09-09	XAIR	2.56	0.01	0.01	4175
2025-09-10	XAIR	2.25	0.01	0.00	5204
2025-09-11	XAIR	2.29	0.01	0.00	5204
2025-09-12	XAIR	2.45	0.01	999.99	5226
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	XAIR	2.31	-	-	-2.25
2025-08-18	XAIR	2.39	-	-	-2.25
2025-08-19	XAIR	2.29	-	-	-2.25
2025-08-20	XAIR	2.13	-	-	-2.25
2025-08-21	XAIR	2.04	-	-	-2.25
2025-08-22	XAIR	2.23	-	-	-2.25
2025-08-25	XAIR	2.28	-	-	-2.25
2025-08-26	XAIR	2.25	-	-	-2.25
2025-08-28	XAIR	2.18	-	-	-2.25
2025-08-29	XAIR	2.19	-	-	-2.25
2025-09-02	XAIR	2.20	-	-	-2.25
2025-09-03	XAIR	2.33	-	-	-2.25
2025-09-04	XAIR	2.15	-	-	-2.25
2025-09-05	XAIR	2.21	-	-	-2.25
2025-09-08	XAIR	3.31	-	-	-2.25
2025-09-09	XAIR	2.55	-	-	-2.25
2025-09-10	XAIR	2.25	-	-	-2.25
2025-09-11	XAIR	2.26	-	-	-2.25
2025-09-12	XAIR	2.45	-	-	-2.25
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	XAIR	31.71	0	38.24
2025-08-18	XAIR	31.71	20.06	8.52
2025-08-19	XAIR	157.11	20.06	8.52
2025-08-20	XAIR	157.08	20.06	8.52
2025-08-21	XAIR	157.02	20.06	8.52
2025-08-22	XAIR	156.17	20.06	8.52
2025-08-25	XAIR	156.00	-41.43	8.52
2025-08-26	XAIR	156.00	-41.43	8.52
2025-08-27	XAIR	156.06	-41.43	9.84
2025-08-28	XAIR	156.10	-41.43	9.84
2025-08-29	XAIR	156.06	-41.43	9.84
2025-09-02	XAIR	156.15	-41.56	9.57
2025-09-03	XAIR	193.69	-41.56	9.57
2025-09-04	XAIR	193.65	-41.56	9.57
2025-09-05	XAIR	193.69	-41.56	9.57
2025-09-08	XAIR	193.65	-41.81	9.57
2025-09-09	XAIR	193.65	-41.81	9.57
2025-09-10	XAIR	193.64	-41.81	9.57
2025-09-11	XAIR	193.72	-41.81	6.79
2025-09-12	XAIR	188.56	-41.81	6.54
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.53

Avg. EPS Est. Current Quarter

-0.26

Avg. EPS Est. Next Quarter

-0.25

Insider Transactions

188.56

Institutional Transactions

-41.81

Beta

0.28

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.3

Max Drawdown 5-Year %

-99.3

Target Price

11.2

P/E

Forward P/E

PEG

P/S

2.73

P/B

1.15

P/Free Cash Flow

EPS

-11.95

Average EPS Est. Cur. Y

-2.25

EPS Next Y. (Est.)

-0.85

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-880.72

Relative Volume

0.17

Return on Equity vs Sector %

-449.1

Return on Equity vs Industry %

-442.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.68

EBIT Estimation

Beyond Air, Inc.

Sector: Healthcare

Industry: Medical Devices

Employees: 61

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

stock quote shares XAIR – Beyond Air Inc Stock Price stock today

news today XAIR – Beyond Air Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch XAIR – Beyond Air Inc yahoo finance google finance

stock history XAIR – Beyond Air Inc invest stock market

stock prices XAIR premarket after hours

ticker XAIR fair value insiders trading

WBA – Walgreens Boots Alliance Inc

Float Short %

2.61

Margin Of Safety %

-27

Put/Call OI Ratio

EPS Next Q Diff

0.07

EPS Last/This Y

EPS This/Next Y

-0.18

Price

11.98

Target Price

11.45

Analyst Recom

Performance Q

7.06

Relative Volume

Beta

0.82

Ticker: WBA

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	WBA	11.96	0.73	0.42	766112
2025-08-18	WBA	11.99	0.77	2.16	758766
2025-08-19	WBA	12.06	0.81	0.45	768120
2025-08-20	WBA	12.19	0.82	0.07	773514
2025-08-21	WBA	12.18	0.80	0.39	785919
2025-08-22	WBA	12.08	0.81	0.73	792053
2025-08-25	WBA	12	0.82	0.48	772613
2025-08-26	WBA	11.92	0.84	0.31	808986
2025-08-27	WBA	12	0.92	0.06	788968
2025-08-28	WBA	11.98	0.92	0.05	788968
2025-08-29	WBA	11.98	0.92	0.05	788968
2025-09-02	WBA	11.98	0.92	0.05	788968
2025-09-03	WBA	11.98	0.92	0.05	788968
2025-09-04	WBA	11.98	N/A	N/A	0
2025-09-05	WBA	11.98	N/A	N/A	0
2025-09-08	WBA	11.98	N/A	N/A	0
2025-09-09	WBA	11.98	N/A	N/A	0
2025-09-10	WBA	11.98	N/A	N/A	0
2025-09-11	WBA	11.98	N/A	N/A	0
2025-09-12	WBA	11.98	N/A	N/A	0
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

12 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	WBA	11.97	-33.5	5943.5	1.73
2025-08-18	WBA	11.99	-33.5	5944.8	1.73
2025-08-19	WBA	12.08	-33.5	5945.5	1.73
2025-08-20	WBA	12.18	-33.5	5945.7	1.73
2025-08-21	WBA	12.18	-33.5	5944.1	1.73
2025-08-22	WBA	12.08	-33.5	5942.9	1.73
2025-08-25	WBA	11.98	-33.5	5943.2	1.73
2025-08-26	WBA	11.92	-33.5	5943.7	1.73
2025-08-27	WBA	12.00	-33.5	5945.5	1.73
2025-08-28	WBA	11.98	-33.5	5945.2	1.73
2025-08-29	WBA	11.98	-33.5	5945.2	1.73
2025-09-02	WBA	11.98	-33.6	5944.4	1.71
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

12 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	WBA	0.00	-3.69	3.24
2025-08-18	WBA	0.00	-5.56	3.24
2025-08-19	WBA	0.00	-5.56	3.24
2025-08-20	WBA	0.00	-5.56	3.24
2025-08-21	WBA	0.00	-5.56	3.24
2025-08-22	WBA	0.00	-5.56	3.24
2025-08-25	WBA	0.00	-1.22	3.24
2025-08-26	WBA	0.00	-1.22	3.24
2025-08-27	WBA	0.00	-1.22	3.17
2025-08-28	WBA	0.00	-1.22	3.17
2025-08-29	WBA	0.00	-1.22	3.17
2025-09-02	WBA	0.00	0	2.61
2025-09-03	WBA	0.00	0	2.61
2025-09-04	WBA	0.00	0	2.61
2025-09-05	WBA	0.00	0	2.61
2025-09-08	WBA	0.00	0	2.61
2025-09-09	WBA	0.00	0	2.61
2025-09-10	WBA	0.00	0	2.61
2025-09-11	WBA	0.00	0	2.61
2025-09-12	WBA	0.00	0	2.61
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.38

Avg. EPS Est. Current Quarter

0.26

Avg. EPS Est. Next Quarter

0.45

Insider Transactions

Institutional Transactions

Beta

0.82

Average Sales Estimate Current Quarter

36770

Average Sales Estimate Next Quarter

37265

Fair Value

8.69

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-82.4

Target Price

11.45

P/E

Forward P/E

PEG

P/S

0.07

P/B

1.44

P/Free Cash Flow

17.88

EPS

-7.29

Average EPS Est. Cur. Y

1.71

EPS Next Y. (Est.)

1.53

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-4.07

Relative Volume

Return on Equity vs Sector %

-112.5

Return on Equity vs Industry %

-77.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

5944.4

Walgreens Boots Alliance, Inc.

Sector: Healthcare

Industry: Pharmaceutical Retailers

Employees: 193000

Walgreens Boots Alliance, Inc. operates as a healthcare, pharmacy, and retail company in the United States, Germany, the United Kingdom, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise. The International segment offers sale of prescription drugs and health and wellness, beauty, personal care, and other consumer products outside the United States; and operates pharmacy-led health and beauty retail businesses under the Boots brand stores in the United Kingdom, the Republic of Ireland, and Thailand, as well as the Benavides brand in Mexico and the Ahumada brand in Chile. The U.S. Healthcare segment provides VillageMD, a national provider of value-based care with primary, multi-specialty, and urgent care providers serving patients in traditional clinic settings, in patients' homes and online appointments; Shields, a specialty pharmacy integrator and accelerator for hospitals; and CareCentrix, a participant in the post-acute and home care management sectors. Walgreens Boots Alliance, Inc. was founded in 1909 and is headquartered in Deerfield, Illinois.

stock quote shares WBA – Walgreens Boots Alliance Inc Stock Price stock today

news today WBA – Walgreens Boots Alliance Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch WBA – Walgreens Boots Alliance Inc yahoo finance google finance

stock history WBA – Walgreens Boots Alliance Inc invest stock market

stock prices WBA premarket after hours

ticker WBA fair value insiders trading

UTMD – Utah Medical Products, Inc.

Float Short %

3.7

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

61.94

Target Price

65.23

Analyst Recom

Performance Q

8.63

Relative Volume

0.36

Beta

0.33

Ticker: UTMD

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	UTMD	55.71	N/A	N/A	0
2025-08-18	UTMD	57.42	N/A	N/A	0
2025-08-19	UTMD	58.56	N/A	N/A	0
2025-08-20	UTMD	58.6	N/A	N/A	0
2025-08-21	UTMD	58.15	N/A	N/A	0
2025-08-22	UTMD	61.25	N/A	N/A	0
2025-08-25	UTMD	60.39	N/A	N/A	0
2025-08-26	UTMD	60.74	N/A	N/A	0
2025-08-27	UTMD	61.17	N/A	N/A	0
2025-08-28	UTMD	62.06	N/A	N/A	0
2025-08-29	UTMD	62.0575	N/A	N/A	0
2025-09-02	UTMD	61.5	N/A	N/A	0
2025-09-03	UTMD	61.47	N/A	N/A	0
2025-09-04	UTMD	62.61	N/A	N/A	0
2025-09-05	UTMD	63.3	N/A	N/A	0
2025-09-08	UTMD	62.98	N/A	N/A	0
2025-09-09	UTMD	62.67	N/A	N/A	0
2025-09-10	UTMD	60.6	N/A	N/A	0
2025-09-11	UTMD	62.94	N/A	N/A	0
2025-09-12	UTMD	61.87	N/A	N/A	0
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	UTMD	55.75	-	-	-
2025-08-18	UTMD	57.20	-	-	-
2025-08-19	UTMD	58.39	-	-	-
2025-08-20	UTMD	57.90	-	-	-
2025-08-21	UTMD	58.46	-	-	-
2025-08-22	UTMD	61.06	-	-	-
2025-08-25	UTMD	60.64	-	-	-
2025-08-26	UTMD	60.74	-	-	-
2025-08-28	UTMD	62.06	-	-	-
2025-08-29	UTMD	62.21	-	-	-
2025-09-02	UTMD	61.84	-	-	-
2025-09-03	UTMD	60.93	-	-	-
2025-09-04	UTMD	62.65	-	-	-
2025-09-05	UTMD	63.40	-	-	-
2025-09-08	UTMD	63.35	-	-	-
2025-09-09	UTMD	63.05	-	-	-
2025-09-10	UTMD	60.49	-	-	-
2025-09-11	UTMD	62.54	-	-	-
2025-09-12	UTMD	61.94	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	UTMD	0.00	-2.52	3.73
2025-08-18	UTMD	0.00	-7.03	3.73
2025-08-19	UTMD	0.00	-7.03	3.73
2025-08-20	UTMD	0.00	-7.03	3.73
2025-08-21	UTMD	0.00	-7.03	3.73
2025-08-22	UTMD	0.00	-7.03	3.73
2025-08-25	UTMD	0.00	-2.19	3.73
2025-08-26	UTMD	0.00	-2.19	3.73
2025-08-27	UTMD	0.00	-2.19	3.95
2025-08-28	UTMD	0.00	-2.19	3.95
2025-08-29	UTMD	0.00	-2.19	3.95
2025-09-02	UTMD	0.00	-2.46	3.95
2025-09-03	UTMD	0.00	-2.46	3.95
2025-09-04	UTMD	0.00	-2.46	3.95
2025-09-05	UTMD	0.00	-2.46	3.95
2025-09-08	UTMD	0.00	-2.46	3.95
2025-09-09	UTMD	0.00	-2.46	3.95
2025-09-10	UTMD	0.00	-2.46	3.95
2025-09-11	UTMD	0.00	-2.46	3.70
2025-09-12	UTMD	0.00	-2.46	3.70
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-2.46

Beta

0.33

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

67.45

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

53.7

Max Drawdown 5-Year %

-55.6

Target Price

65.23

P/E

16.67

Forward P/E

PEG

P/S

5.14

P/B

1.7

P/Free Cash Flow

14.47

EPS

3.74

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

32.33

Relative Volume

0.36

Return on Equity vs Sector %

-14.2

Return on Equity vs Industry %

1.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Utah Medical Products, Inc.

Sector: Healthcare

Industry: Medical Instruments & Supplies

Employees: 155

Utah Medical Products, Inc. provides medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company also provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. The company serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

stock quote shares UTMD – Utah Medical Products, Inc. Stock Price stock today

news today UTMD – Utah Medical Products, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch UTMD – Utah Medical Products, Inc. yahoo finance google finance

stock history UTMD – Utah Medical Products, Inc. invest stock market

stock prices UTMD premarket after hours

ticker UTMD fair value insiders trading

No more stocks to show

ZCMD – Zhongchao Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ZCMD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

XTLB – X.T.L. Biopharmaceuticals Ltd. ADR

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: XTLB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y